Drug Profile
Plerixafor - Sanofi
Alternative Names: AMD 3100; JM 3100; LM-3100; Mozobil; Plerixafor-hydrochloride; SDZ SID 791Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Genzyme Corporation; Rega Institute for Medical Research
- Developer Dana-Farber Cancer Institute; Memorial Sloan-Kettering Cancer Center; Sanofi
- Class Antineoplastics; Heterocyclic compounds; Polyamines; Small molecules
- Mechanism of Action CXCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Stem cell mobilisation
- Phase II Glioma
- Phase I/II Acute myeloid leukaemia; Multiple myeloma
- Phase I Pancreatic cancer
- No development reported Chronic lymphocytic leukaemia; Colorectal cancer; Myocardial infarction; Ovarian cancer; Sickle cell anaemia
- Discontinued HIV infections; Rheumatoid arthritis
Most Recent Events
- 29 Nov 2022 Phase-II development for Glioma and Glioblastoma (Combination therapy, Late-stage disease, Newly diagnosed) is ongoing in USA (IV) (NCT03746080)
- 28 Aug 2020 No recent reports of development identified for phase-I development in Colorectal-cancer(Late-stage disease, Second-line therapy or greater) in United Kingdom (IV, Infusion)
- 28 Aug 2020 No recent reports of development identified for phase-I development in Ovarian-cancer(Late-stage disease, Second-line therapy or greater) in United Kingdom (IV, Infusion)